CD40 and neoplasm: Similarly, in subcutaneous PDAC models, mice treated with anti-IL-1R1 antibodies showed accelerated tumor growth compared with the untreated group, and treatment with the combination of anti-IL-1R1 and agonistic CD40 antibodies performed worse than agonistic CD40 antibody monotherapy (Fig. 2c).